Español 
English
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región.
Artículos Relacionados
-
UDIBI
The dialyzable leukocyte extract TransferonTM inhibits tumor growth and brain metastasis in a murine model of prostate cancer. VER...
-
UDIBI
Colloids and Surfaces A: Physicochemical and Engineering Aspects. Structural and physicochemical characteristics of one-step PAMAM dendrimeric nanoparticles. VER MÁS
-
UDIBI
Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug. VER MÁS
-
UDIBI
Fecha de publicación: 2 abril de 2020 Development and Evaluation of a Set of Spike and Receptor Binding Domain‐Based...
-
-
UDIBI
Development of Functional Antibodies Directed to Human Dialyzable Leukocyte Extract (Transferon®). VER MÁS
-
UDIBI
Isolation and characterization of high affinity and highly stable anti-Chikungunya virus antibodies using ALTHEA Gold Libraries™. VER MÁS
-
UDIBI
Fecha de publicación: 6 de septiembre de 2022 In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2...
